Ropinirole 0.25 mg Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
2004-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to compare the relative bioavailability of the test
formulation of Ropinirole (TEVA Pharmaceuticals USA) with already marketed reference of
Requip® (Manufactured by SmithKline Beecham Pharmaceuticals for GlaxoSmithKline) under
fasting conditions in healthy, non-smoking, adult subjects.